• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Akari Therapeutics plc filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    7/1/25 5:30:29 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKTX alert in real time by email
    8-K
    falsetrue00015411570001541157aktx:OrdinarySharesParValue0.0001PerShareMember2025-06-302025-06-3000015411572025-06-302025-06-300001541157dei:AdrMember2025-06-302025-06-30

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 30, 2025

     

    Akari Therapeutics, Plc

    (Exact Name of Registrant as Specified in Charter)

    England and Wales

    001-36288

    98-1034922

    (State or other jurisdiction
    of incorporation)

    (Commission File Number)

    (I.R.S. Employer
    Identification No.)

    22 Boston Wharf Road FL 7

    Boston, MA 02210

    (Address, including zip code, of Principal Executive Offices)

    Registrant’s telephone number, including area code: (929) 274-7510

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ¨

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ¨

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ¨

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ¨

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:

     

    Trading Symbol(s)

     

    Name of each

    exchange on which registered

    American Depositary Shares, each representing 2,000 Ordinary Shares

     

    AKTX

     

    The Nasdaq Capital Market

    Ordinary Shares, par value $0.0001 per share*

     

     

     

     

    *Trading, but only in connection with the American Depositary Shares.

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     


     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    As noted below under Item 5.07, at the 2025 Annual General Meeting (the “Annual General Meeting”) of Akari Therapeutics, Plc (the “Company”), held on June 30, 2025, the Company’s shareholders approved an increase in the number of shares available for the grant of awards under the Company’s 2023 Equity Incentive Plan (the “2023 Plan”) by 11,026,000,000 ordinary shares (the equivalent of 5,513,000 American Depositary Shares (“ADSs”)) to 19,806,000,000 ordinary shares (the equivalent of 9,903,000 ADSs) plus such additional number of ordinary shares (up to 855,637,300 ordinary shares) subject to awards granted under the Celsus Therapeutics PLC 2014 Equity Incentive Plan (the “2014 Plan”), to the extent such awards are forfeited or cancelled, or expire unexercised.

    A description of the material terms of the 2023 Plan was included in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on June 6, 2025 (the “Proxy Statement”) under “Resolution 12: To generally and unconditionally authorize an increase in the number of shares available under the 2023 Plan” and is incorporated herein by reference.

    The description in the Proxy Statement does not purport to be complete, and is qualified in its entirety by reference to the full text of the 2023 Plan as amended by Amendment No. 2 to the Akari Therapeutics, PLC 2023 Equity Incentive Plan, a copy of which is included as Exhibit 10.1 hereto and is incorporated herein by reference.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

    On June 30, 2025, the Company held its Annual General Meeting. Proxies were solicited pursuant to the Company’s Proxy Statement, with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. The number of ordinary shares entitled to vote at the Annual General Meeting was 65,229,461,523. The number of ordinary shares present or represented by valid proxy at the Annual General Meeting established a quorum for the Annual General Meeting. The Annual General Meeting duly proceeded in accordance with the provisions of the articles of association of the Company and all matters submitted to a vote of the Company’s shareholders at the Annual General Meeting were approved and the director nominees were elected.

    The voting results below are final and reported in ordinary shares.

     

    Ordinary Resolution

    For

    Against

    Abstain

    To receive the report of the Board of Directors and the accounts for the year ended December 31, 2024, together with the report of the statutory auditor and the strategic report.

    41,421,403,229

    56,560,000

    488,000

    To approve, on an advisory-basis, the Board of Directors’ Remuneration Report (excluding the Board of Directors’ Remuneration Policy), as set out in the Company’s annual report and accounts for the financial year ended December 31, 2024.

    27,472,675,229

    528,262,000

    13,477,514,000

    To re-elect Hoyoung Huh as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Company’s articles of association (the “Articles”).

    27,913,031,229

    257,706,000

    13,307,714,000

    To re-elect Robert Bazemore as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.

    27,866,417,229

    164,118,000

    13,447,916,000

    To re-elect James Neal as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.

    27,780,995,229

    397,490,000

    13,299,966,000

    To re-elect Sandip I. Patel as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.

    27,930,183,229

    16,000,000

    13,532,268,000

    To re-elect Samir R. Patel as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.

    28,033,241,229

    151,248,000

    13,293,962,000

     


     

    To re-elect Abizer Gaslightwala as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.

    28,003,287,229

    151,198,000

    13,323,966,000

    To ratify the appointment of BDO USA, P.C. as independent registered public accounting firm of Akari for the year ending December 31, 2025.

    41,446,115,229

    32,200,000

    136,000

    To re-appoint HaysMac LLP as statutory auditors of Akari to hold office until the conclusion of the next annual general meeting at which accounts are laid before Akari shareholders.

    41,244,329,229

    179,188,000

    54,934,000

    To authorize the audit committee of the Board of Directors of Akari to fix the statutory auditors’ remuneration.

    41,471,695,229

    6,498,000

    258,000

    To generally and unconditionally authorize an increase in the number of shares available for the grant of awards under the 2023 Plan by 11,026,000,000 ordinary shares (the equivalent of 5,513,000 American Depositary Shares (“ADSs”)) to 19,806,000,000 ordinary shares (the equivalent of 9,903,000 ADSs) plus such additional number of ordinary shares (up to 855,637,300 ordinary shares) subject to awards granted under the 2014 Plan, to the extent such awards are forfeited or cancelled, or expire unexercised.

    27,514,871,229

    632,085,000

    13,331,495,000

    To approve, on a non-binding, advisory basis, the compensation of our named executive officers (“NEOs”) as disclosed in the Proxy Statement.

    27,983,922,229

    188,498,000

    13,306,031,000

    To approve the time-vested one time grant stock option awards over 225,000 ADSs (representing 450,000,000 ordinary shares) granted, conditional on shareholder approval, to each of certain of the Company’s directors (being Hoyoung Huh, Raymond Prudo-Chlebosz, Robert Bazemore, James Neal, Sandip I. Patel and Samir R. Patel) on March 20, 2025 (the “Stock Option Awards”), which would represent, in aggregate, time-vested one time grant options over 1,350,000 ADSs (representing 2,700,000,000 ordinary shares) (4.2% of the Company’s current issued share capital) with each of the Stock Option Awards vesting 25% on March 20, 2025, 25% at December 31, 2025 and the remaining 50% vesting monthly over the next 24 months thereafter.

    27,512,696,229

    634,230,000

    13,331,525,000

    That, in accordance with section 551 of the U.K. Companies Act 2006, our directors or any duly authorized committee of the directors be generally and unconditionally authorized to allot shares in Akari and to grant rights to subscribe for or to convert any security into shares in Akari up to an aggregate nominal amount of USD 20,000,000 for a period expiring (unless otherwise renewed, varied or revoked by Akari at a general meeting) on June 30, 2030 (the “General Allotment Proposal”), save that Akari may, before such expiry, make offers or agreements which would or might require such shares to be allotted or such rights to be granted after such expiry and the directors may allot such shares or grant such rights in pursuance of such offers or agreements notwithstanding that the authority conferred by this resolution has expired; and this resolution revokes and replaces all unexercised authorities previously granted to the directors to allot shares or grant rights to subscribe for or convert any security into shares, but without prejudice to any allotment of shares or grant of rights already made, offered or agreed to be made pursuant to such authorities.

    40,641,456,229

    671,412,000

    165,583,000

     


     

    Special Resolution

    For

    Against

    Abstain

    That, conditional the General Allotment Proposal being duly passed, in accordance with section 570 of the U.K. Companies Act 2006, the directors of Akari (or any duly authorized committee of the directors of Akari) be generally empowered to allot equity securities (as defined in section 560 of the U.K. Companies Act 2006) for cash pursuant to the authorization conferred on them by the General Allotment Proposal as if section 561 of the U.K. Companies Act 2006 and any pre-emption provisions in the Articles (or howsoever otherwise arising) did not apply to the allotment for a period expiring (unless previously renewed, varied or revoked by Akari prior to or on that date) five years after the date on which this resolution is passed save that Akari may, before such expiry, make an offer or agreement which would or might require shares to be allotted after such expiry and the directors may allot shares in pursuance of any such offer or agreement notwithstanding that the power conferred by this resolution has expired.

     

    40,604,284,229

    204,784,000

    669,383,000


     

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit No.

     

    Description

    10.1

     

    Amendment No. 2 to the Akari Therapeutics, PLC 2023 Equity Incentive Plan

    104

     

    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Akari Therapeutics, Plc

    Date: July 1, 2025

    By:

    /s/ Torsten Hombeck

    Torsten Hombeck

    Chief Financial Officer

     

     


    Get the next $AKTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTX

    DatePrice TargetRatingAnalyst
    7/18/2025$5.00Buy
    Maxim Group
    More analyst ratings

    $AKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Akari Therapeutics with a new price target

    Maxim Group initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $5.00

    7/18/25 9:02:34 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Gaslightwala Abizer bought $7,120 worth of American Depositary Shares representing Ordinary Shares (6,146 units at $1.16), increasing direct ownership by 2% to 277,574 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/25/25 4:30:04 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Gaslightwala Abizer bought $12,000 worth of American Depositary Shares representing Ordinary Shares (10,000 units at $1.20), increasing direct ownership by 4% to 271,428 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/24/25 4:30:10 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Gaslightwala Abizer bought $18,000 worth of American Depositary Shares representing Ordinary Shares (15,000 units at $1.20), increasing direct ownership by 6% to 261,428 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/20/25 4:05:04 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    SEC Filings

    View All

    Akari Therapeutics plc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Akari Therapeutics Plc (0001541157) (Filer)

    8/19/25 8:00:23 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Akari Therapeutics plc

    10-Q - Akari Therapeutics Plc (0001541157) (Filer)

    8/13/25 5:01:23 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Akari Therapeutics plc

    EFFECT - Akari Therapeutics Plc (0001541157) (Filer)

    8/1/25 12:15:28 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

    BOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date and Time: Tuesday, August 19, 2025 at 2:00 PM ET Presenter: Abizer Gaslightwala, President and Chief Executive Officer of AkariRegistration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed

    8/14/25 9:15:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Releases Virtual Investor "What This Means" Segment

    Watch the "What This Means" video here BOSTON and LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced that Abizer Gaslightwala, President and CEO of Akari Therapeutics participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr. Gaslightwala discussed its novel spliceosome modulator payload, PH1, and the Company's ongoing efforts to build on key data for its spliceosome modulator payload with further research ongoing on how the payload can also disrupt key drivers responsible for c

    7/29/25 9:15:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

    PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company advancing pipeline of ADCs using PH1 payload across both Trop2 and an undisclosed target Emerging new preclinical data on impact of PH1 payload against a key oncogenic driver is expected before year-end BOSTON and LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today reiterated its commitment to ongoing research to better understand the multiple effects of its novel spliceosome modulator,

    7/23/25 8:55:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Gaslightwala Abizer bought $7,120 worth of American Depositary Shares representing Ordinary Shares (6,146 units at $1.16), increasing direct ownership by 2% to 277,574 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/25/25 4:30:04 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Gaslightwala Abizer bought $12,000 worth of American Depositary Shares representing Ordinary Shares (10,000 units at $1.20), increasing direct ownership by 4% to 271,428 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/24/25 4:30:10 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Gaslightwala Abizer bought $18,000 worth of American Depositary Shares representing Ordinary Shares (15,000 units at $1.20), increasing direct ownership by 6% to 261,428 units (SEC Form 4)

    4 - Akari Therapeutics Plc (0001541157) (Issuer)

    6/20/25 4:05:04 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Financials

    Live finance-specific insights

    View All

    Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

    BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London, shareholders approved the Company's issuance of shares in connection with the proposed merger, with approximately 99% of shares present at the General Meeting, in person or by proxy, voted in support. "I am thrilled to announce this

    11/8/24 8:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger

    BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. The Form S-4 was declared effective by the SEC on October 11, 2024 allowing the Company to definitively schedule the General Meeting to be held in relation to the merger. The General Meeting will be held at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London. "I am so excited to be

    10/15/24 8:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders

    Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, in follow up to the May 1st announcement that Samir R. Patel, M.D., has assumed the role of Interim President & CEO, provides detail of Dr. Patel's employment compensation. Dr Patel's employment contract reaffirms his desire to align his success directly with the success of the company's shareholders. Dr. Patel will be compen

    6/5/24 8:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Leadership Updates

    Live Leadership Updates

    View All

    Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

    NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member.  We look forward to following her vision and continued leadership as we

    5/19/25 8:00:00 AM ET
    $AKTX
    $CRBP
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

    Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record across oncology therapeutics including ADCs and antibody therapies ranging from early discovery to pre-clinical/clinical stage 25+ year-career experience bolsters Company's efforts to address growing, high-value ADC market and maximize opportunities for non-dilutive capital BOSTON and LONDON, May 01, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the appointment of Mark F. Kubik as Head of Business Development

    5/1/25 8:45:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

    Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued progress of lead program, AKTX-101, for the treatment of solid tumors Platform technology to fuel pipeline with ability to generate novel ADC candidates across a range of solid/hematological cancers Leveraging opportunities for non-dilutive capital through partnering of legacy pipeline Cash on hand expected to be sufficient to fund planned operations into September 2025 BOSTON and LONDON, April 16, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-fun

    4/16/25 8:00:00 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    12/6/24 4:00:28 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

    SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

    6/20/24 7:30:07 AM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Akari Therapeutics plc

    SC 13D - Akari Therapeutics Plc (0001541157) (Subject)

    6/18/24 4:15:30 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care